Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


Soluble Form of Herpesvirus Entry Mediator (HVEM) Is Elevated in Sera of Active Collagen-Vascular Diseases and Might Be a New Biomarker of Disease Activity.

Arai,  Satoko, Kurasawa,  Kazuhiro, Okada,  Harutsugu, Ohwada,  Takayoshi, Maezawa,  Reika, Fukuda,  Takeshi

Background/Purpose:

Herpesvirus entry mediator (HVEM), a member of TNF receptor superfamily, regulates immune-responses. HVEM binds to LIGHT to activate both interacting cells. In addition, HUVEM interacts with BTLA and CD160 to deliver negative signals. Animal studies have shown that HVEM/ LIGHT/ BTLA/ CD160 interactions are involved in the development of autoimmune diseases. However, role of these molecules in human collagen-vascular diseases are not fully clarified.

The aim of this study are to determine whether there exists soluble form of HVEM (sHVEM) in sera from CVDs, and to clarify clinical importance of sHVEM in CVDs.

Methods:

We developed a EIA system for detection of sHVEM and examined sera before treatment from SLE(n=44), RA(n=63), scleroderma(SSc)(n=21), vasculitis(n=21), and healthy controls(n=42). Clinical features of the patients were examined by reviewing medical records.

Results:

Serum levels of sHVEM in controls were 1.93+0.85ng/ml. Soluble HVEM levels were significantly elevated in sera from CVDs (Fig.). The levels were 5.27+2.31 (average+ s.d.) in SLE, 4.50+2.23 in RA, 3.99+1.57 in SSc and 7.84+3.99 ng/ml. When cut-off level was determined as 3.63 ng/ml (average +2SD), elevation of s HVEM was found in 72.7% of SLE, 66.6% of RA, 52.3% of SSc and 95.2% of vasculitis.

In SLE, patients with low complement levels or high anti-DNA titers showed high sHVEM levels compared to those without the abnormalities. No significant relation was found between sHVEM levels and organ involvements. In RA, sHVEM levels from patients with moderate to high disease activity were higher than those with remission or low disease activity. In vasculitis, patients with more extended organ involvements had higher sHVEM levels. Moreover, immunosuppressive therapy reduced sHVEM levels significantly in SLE, RA and vasculitis.

Conclusion:

Soluble form of HVEM exists in human sera. Serum levels of sHVEM were significantly elevated in varieties of CVDs compared to controls. The elevation of sHVEM reflects disease activity and treatment reduced titer of the molecules. Soluble form of HVEM could be a candidate of new biomarker of disease activity of CVDs.

To cite this abstract, please use the following information:
Arai, Satoko, Kurasawa, Kazuhiro, Okada, Harutsugu, Ohwada, Takayoshi, Maezawa, Reika, Fukuda, Takeshi; Soluble Form of Herpesvirus Entry Mediator (HVEM) Is Elevated in Sera of Active Collagen-Vascular Diseases and Might Be a New Biomarker of Disease Activity. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :1403
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP